Today: 11 June 2026
Rigetti’s Quantum Leap: Stock Jumps 5,000% and Then Grinds Back – Bubble or Breakthrough?
24 October 2025
3 mins read

Rigetti’s Quantum Leap: Stock Jumps 5,000% and Then Grinds Back – Bubble or Breakthrough?

  • Extreme rally and pullback: Rigetti Computing (NASDAQ: RGTI) stock has had a roller-coaster few months, soaring roughly 5,000% in 2025 (from under $1 to ~$56 on Oct. 15) . After hitting that all-time high (52-week range $0.36–$58.15), RGTI plunged about 25% in late October, sliding into the high-$30s. It closed at $39.60 on Oct. 23 (up +9.8% on the day) and traded around $40.98 in pre-market on Oct. 24 . Even after the retracement, the stock remains up thousands of percent year-over-year .
  • Recent catalysts: Investors credit several news items. In late Sept. Rigetti (with partner QphoX) won a $5.8M Air Force contract for quantum networking and booked roughly $5.7M in orders for two new “Novera” quantum computers (delivery in 2026) ts2.tech. The company also launched a new 36-qubit, multi-chip processor on its cloud platform ts2.tech datacenterdynamics.com. Those achievements lent real-world credibility to the stock’s rise. More recently, a news report on Oct. 22 said the U.S. government is considering taking equity stakes in quantum firms (including Rigetti) in exchange for R&D funding reuters.com. That rumor sent RGTI +15.6% on Oct. 23 ts2.tech (ahead of official denials), highlighting how policy buzz can swing the stock.
  • Financials and outlook: Rigetti remains an early-stage company. Q2 2025 GAAP revenue was only $1.8 million (down ~42% YoY) with a $39.7M net loss. Operating expenses are large (Q2 OpEx ~$20.4M ) as the company pours cash into R&D. Importantly, Rigetti finished Q2 with about $571.6M in cash (after a $350M equity raise) . Analysts expect similarly modest sales in Q3 (~$2M) and continued losses; Rigetti will report its next quarterly results in November.
  • Valuation and analyst views: At current prices, Rigetti’s valuation is astronomical – roughly 1,500× trailing sales by some measures ts2.tech reuters.com. Market cap is on the order of $13–18 billion despite only single-digit millions in revenue. Wall Street is bullish long-term (TipRanks shows a unanimous “Strong Buy” consensus) ts2.tech, but forecasts are far below today’s price. For example, Benchmark’s highest 12‑month target is $50 (+8% upside) ts2.tech, and most analysts’ targets sit in the mid-$20s (roughly 40–50% below recent trading levels) ts2.tech ts2.tech. In other words, many brokers view the stock as overextended. One Seeking Alpha analyst even calls RGTI “massively overvalued” given its ~$17–18B market cap and lack of near-term profits ts2.tech.
  • Quantum sector context: Rigetti is not alone in this frenzy. Peer quantum startups have also skyrocketed: trapped-ion specialist IonQ is up ~700% YTD and quantum-annealing pioneer D-Wave is up ~3,000–4,000% ts2.tech. Big-tech firms are racing too. Just last week Google announced its new “Willow” quantum chip achieved a “first-ever verifiable quantum advantage,” running an algorithm 13,000× faster than a top classical supercomputer ndtv.com. Microsoft and IBM have likewise stated that practical quantum machines are on the horizon reuters.com. Policymakers are also throwing weight behind quantum: on Oct. 23 media cited Commerce Dept. talks to back startups (continuing a trend of government equity in tech reuters.com). (Rigetti said it is “continuously engaging with the U.S. government on funding opportunities” investopedia.com.) All this has made quantum computing a headline theme, lifting sector ETFs and retail trading activity.
  • Expert commentary and sentiment: The mood is electric but mixed with caution. Traders and commentators note the parabolic run-up looks eerily like a bubble. Barron’s recently warned quantum stocks “may keep inflating” until they are “tested by fundamentals” ts2.tech. On the other hand, some strategists highlight the disruptive potential: IG Markets analyst Chris Beauchamp said the administration believes quantum “offers the chance to really revolutionize the U.S. economy” reuters.com. Rigetti’s CEO Kulkarni similarly stressed his team’s progress and confidence in its roadmap datacenterdynamics.com. In the short term, many analysts expect volatility. As one tech newsletter put it, the stocks “may have bit off more than they can chew,” noting that former speculative booms eventually come down to earth ts2.tech.

In summary, Rigetti’s stock has been on a dizzying climb fueled by tangible tech wins and speculative fervor. Its recent pullback illustrates that even high-flying quantum names can wobble as “reality catches up to hype” ts2.tech. The company’s next few quarters – and any future breakthroughs – will determine if this moonshot can sustainably advance or if it settles back toward earth.

Sources: Market data and analysis from Rigetti investor reports and financial sites ; news of contracts and breakthroughs ; technology and policy developments from Reuters and industry media ; expert quotes and forecasts from financial publications .

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Jobless Claims Hit 4½-Month High Despite Stable Layoffs
    June 11, 2026, 11:14 AM EDT. Jobless claims in the U.S. rose to a 4½-month high in early June, signaling more individuals accessing unemployment benefits. However, this increase does not reflect a surge in layoffs, suggesting businesses are not cutting more jobs even as claims tick up. The data indicates a complex labor market where claims may rise for reasons other than widespread job losses.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Nu Holdings Stock Skyrockets Amid Expansion Ambitions – Latest Price, News & Forecasts
Previous Story

Nu Holdings Stock Skyrockets Amid Expansion Ambitions – Latest Price, News & Forecasts

OpenAI Hires 100 Ex-Bankers at $150/Hour to Train an AI to Replace Wall Street Analysts
Next Story

OpenAI Hires 100 Ex-Bankers at $150/Hour to Train an AI to Replace Wall Street Analysts

Go toTop